The invention discloses a polypeptide for treating Parkinson's
disease. In the application, it is found for the first time that a transient
receptor potential M2 type (TRPM2) channel is expressed more in a fragile DA
neuron subgroup, the expression quantity of the TRPM2 channel is positively correlated with age in a Parkinson's
disease (PD) patient, and an action mechanism is defined through strict experiments, that is, the TRPM2 channel is preferentially activated in an ADE
neuron through a PARP-1 / PARG / ADPR axis to drive Mfn2 / Bcl-2 complex-dependent mitochondrial hyper-fusion, so that the expression quantity of the TRPM2 channel is positively correlated with age; the ADE
neuron death is caused. In addition, the TRPM2 channel also mediates the susceptibility of SNc DA neurons in the mouse treated by
MPTP through Mfn2 / Bcl-2. It is found for the first time that blocking of PARP-1 / PARG / ADPR and Mfn2 / Bcl-2 mediated DA
neuron death pathways can prevent DA
neuron death of a specific
induced pluripotent stem cell (iPSC) source of a patient suffering from the spontaneous Parkinson's
disease (SPD). As susceptible SNc DA
neuron loss is a main symptom of PD, PARP-1 / PARG / ADPR and Mfn2 / Bcl-2 pathways may become new therapeutic targets for PD.